Lundbeck Collaborates with Migraine Community to Raise the Bar for Migraine Care

Audio By Carbonatix

DEERFIELD, Ill.--(BUSINESS WIRE)--Sep 25, 2025--

Despite being one of the leading causes of disability worldwide, migraine disease remains misunderstood, and its impact underestimated by society 1. This is fueled by the risk of disease worsening and lack of recognition around the personal impact of migraine, which may preclude proper preventive care 2. To help address this critical gap, Lundbeck in collaboration with six migraine patient advocacy organizations is launching the “Raise the Bar for Migraine Care” initiative this Pain Awareness Month.

This initiative brings together voices from patient and HCP advocates to spark a new conversation among the community. Data from recent surveys conducted by the American Migraine Foundation (AMF) and the Association of Migraine Disorders (AMD), with funding from Lundbeck, underscore the urgent need for improved quality of life for people living with migraine. In the AMF survey of 511 people with migraine, 92% of people who responded said migraine disease has an extreme or fairly big impact on their life, with 83% of respondents wanting their healthcare provider to know how migraine affects their daily life 3. Furthermore, 49% of people who responded to the AMD survey of 467 people with migraine said their preventive treatment is somewhat or not at all helping to reduce the frequency, severity, or disability of their migraine attacks. And a notable 68% said they are either extremely or moderately worried that their disease frequency and/or severity might increase in the future 4.

“At Lundbeck, we recognize the urgent need to shift the conversation around migraine care from pain and symptom management to a focus on continual improvement for better quality of life for people living with migraine,” said Molly Poarch, Vice President, Corporate Affairs at Lundbeck. “Our collaboration with the migraine community was built on a shared purpose to elevate understanding of migraine as a disabling and progressive disease and redefine migraine care expectations for optimal care, enabling more people to live their lives to the fullest.”

The “Raise the Bar for Migraine Care” initiative champions the belief that better is possible through innovative treatment options, new standards of care, and resources to support more ambitious and individualized treatment goals that go beyond reducing headache and migraine days 5. As part of this initiative, Lundbeck teamed up with leading migraine advocacy organizations to create a comprehensive, easy-to-navigate online resource. The ‘Patient Empowerment Guide’ equips people with curated patient advocacy resources to support them on their path to better days — whether someone is seeking disease information, preparing for more impactful goal-focused conversations with their healthcare providers, or inspiration from others who understand what it’s like to navigate the spectrum of migraine disease.

Patient advocacy organizations collaborating with Lundbeck on this initiative include AMD, AMF, Coalition for Headache and Migraine Patients, Miles for Migraine, National Headache Foundation, and World Health Education Foundation.

“It’s essential for people with migraine to grasp the complexities of this disease — if it’s not well managed, it can escalate and derail your life. Yet, the severity and life impact in each person can be vastly different,” said Paula K. Dumas, President of World Health Education Foundation and Executive Producer of Migraine World Summit. “Years ago, I wasn’t aware of the risks of disease progression and worsened until I reached a breaking point. Today, I'm grateful that better control is possible. I'm passionate about initiatives like this that educate people on better migraine care, with the hopes that fewer people endure the depths of pain and loss associated with this disease over time.”

Learn more about the initiative and new resource here.

About Raise the Bar for Migraine Care
Migraine is a progressive and disabling neurological disease with potentially significant impact that is both underestimated and underappreciated in our society 1. Migraine can have a severe impact, preventing people living with the disease from fully engaging in their personal lives and careers 6. Despite being one of the most common neurological disorders in the world, there remains a lack of education around risk of disease progression and recognition of its holistic impact 1.

With innovative treatment approaches and updated statements from professional migraine organizations striving for optimal control of migraine disease, we believe better is possible 5. Lundbeck is working with the community to raise the bar for migraine care by challenging the status quo and redefining treatment expectations to help people with migraine live their lives to the fullest.

About Migraine Disease
Migraine is a complex and disabling neurological disease that limits functionality and quality of life 1. It is characterized by moderate to severe head pain typically accompanied by an array of symptoms, including nausea, vomiting and sensitivity to light or sound 7. Over time, migraine disease may worsen, with attacks increasing in frequency, severity and duration 2. It is estimated to affect more than 40 million people in the U.S. and impacts three times as many women than men 8. Headache disorders are a leading cause of years lived with disability (YLD) among all diseases and is a top 5 cause for 10–24-year-olds, according to the 2019 Global Burden of Disease study 9. The impact of migraine permeates into career, home life and relationships 6.

About Lundbeck
Lundbeck is a global biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long-term value for our shareholders by making positive contributions to patients, their families and society as a whole.

Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries.

Lundbeck US comprises the wholly owned US subsidiaries of H. Lundbeck A/S (HLUNa / HLUNb, HLUNA DC / HLUNB DC) (“Lundbeck”), including Lundbeck LLC and Lundbeck Pharmaceuticals LLC. For additional information, please visit Lundbeck.com/us and connect with us on LinkedIn and X at @LundbeckUS.

References

View source version on businesswire.com:https://www.businesswire.com/news/home/20250923717592/en/

CONTACT: Brittany Korb

Director, Product Communications and Patient Advocacy

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS

INDUSTRY KEYWORD: HEALTH NEUROLOGY RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: Lundbeck

Copyright Business Wire 2025.

PUB: 09/25/2025 10:17 AM/DISC: 09/25/2025 10:16 AM

http://www.businesswire.com/news/home/20250923717592/en